| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Celairis receives exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa (RP), in Australia, New Zealand, and member states of the Association of Southeast Asian Nations (ASEAN) ... |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Received Provisional Approval and Priority Designation for OCU400 in The Bahamas |
| 15 Oct 2026 |
8-K: Regulation FD Disclosure
Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa |
| 06 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 5, 2026, Ocugen, Inc. (the “Company”) reconvened its Special Meeting of Stockholders (the “Special Meeting”) virtually, which had been adjourned on September 21, 2026 solely with respect to the proposal to approve the adoption... |
| 23 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 21, 2026, Ocugen, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) virtually, which was adjourned to October 5, 2026 solely with respect to the proposal to approve the adoption of an amendm... |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (AMD); on track to initiate Phase 3 this quarter |
| 13 Jul 2026 |
8-K: Other Events
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
On June 11, 2026, Ocugen, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) virtually at 8:00 a.m. ET. At the Annual Meeting, a total of 139,628,075 shares of the Common Stock were represented virtu... |
| 03 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Effective May 29, 2026, Ramesh Ramachandran, CPA, MBA, CMA, resigned as the Chief Accounting Officer of Ocugen, Inc. (the “Company”). Following the resignation of Mr. Ramachandran, who was designated as the Company's principal accounting... |
| 14 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from Ocugen, Inc. (the “Company”) as its Chief Medical Officer. |
| 14 May 2026 |
8-K: Creation of a Direct Financial Obligation; Unregistered Sales of Equity Securities +1 more
Includes Full Exercise of $15.0 million Over-Allotment Option |
| 07 May 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more
INDENTURE dated as of May 7, 2026 between OCUGEN, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, as trus... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p<0.05) 31% reduction in lesion size and 27% EZ preservation (correlated to visual function) in optim... |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
We are a biotechnology company focused on discovering, developing, and commercializing novel gene therapies that improve health and offer hope for patients across the globe. |
| 27 Mar 2026 |
8-K: Regulation FD Disclosure
Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally |
| 24 Mar 2026 |
8-K: Regulation FD Disclosure
Courageous Innovation Dedicated to Bringing Game - Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally |
| 20 Mar 2026 |
8-K: Other Events
As previously disclosed, in August 2025, Ocugen, Inc. (“Ocugen”) closed a registered direct offering, pursuant to a securities purchase agreement with an institutional investor (the “Investor”), for the purchase and sale of 20,000,000 sh... |
| 04 Mar 2026 |
8-K: Other Events
Petitioner Ocugen, Inc. (“Ocugen” or the “Company”), by and through its undersigned counsel, brings this petition (the “Petition”) pursuant to 8 Del. C. § 205 (“Section 205”), seeking to have this Court validate corporate acts and declar... |
Loading...